From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q2 2018 call → NO我们只需要根据提供的文本回答是或否。关键问题是管理层是否描述了公司最近从需要说服的候选者转变为已批准、指定、上市、合格、注册、报销或预先授权的选择,从而进入买方的采购、报销、处方集、规格、采购、网络、目录或计划系统,并且这种准入状态是新的,以至于大部分未来业务尚未反映在报告结果中。 扫描文本中是否有此类描述。管理层讨论了在零售商的货架空间、分销点、类别管理方面的进展,例如“Fix the Mix”计划、增加分销点、说服零售商移除重复的次要品牌等。这些听起来像是常规的销售和分销努力,而不是进入正式的采购系统。没有提到被列入批准的供应商名单、处方集、报销途径或类似内容。提到的“类别管理”和“货架空间”是零售分销,而不是采购系统。此外,任何提及的“新分销”或“货架空间”都是常规的零售销售活动。 关于“品牌食品服务”和“全国和区域客户”的提及,以及“菜单提及”和“前台存在”,这些可能暗示进入菜单或成为指定供应商,但文本没有明确说明公司被列入批准的供应商名单或类似系统。管理层提到“与全国和区域连锁账户的渗透增加”、“新增超过19,000个餐厅地点”等,但这些是销售胜利,而不是系统性的准入状态。 文本中没有任何内容表明公司最近获得了某种正式地位,使得未来业务无需单独销售即可自动流入。所有描述都是关于销售努力、分销增长和营销活动。因此,答案应为“否”。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.